BioSpace News Archive

Galderma announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.

NanoString Technologies, Inc. announced that it has reached an agreement with Patient Square Capital, a prominent health care investment firm, pursuant to which Patient Square will serve as the “stalking horse” bidder in conjunction with a court-supervised sales process.

Arcutis Biotherapeutics, Inc., presented in a late-breaking clinical trial session at the American Academy of Dermatology annual meeting new data from its INTEGUMENT-PED pivotal Phase 3 study of investigational roflumilast cream 0.05% in children 2 to 5 years of age with mild to moderate atopic dermatitis.

Incyte announced new results from a Phase 2 study evaluating the efficacy and safety of twice-daily ruxolitinib cream 1.5% in adult patients with Hurley stage 1 or 2 hidradenitis suppurativa.

Ascletis Pharma Inc. announces the poster presentation of Phase II study final results of ASC40, a first-in-class fatty acid synthase inhibitor for treatment of acne, at the 2024 American Academy of Dermatology Annual Meeting in San Diego, the United States.

Everest Medicines announced the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China, has accepted Everest’s New Drug Application for VELSIPITY® for the treatment of adult patients with moderately to severely active ulcerative colitis.

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis and other important updates at its R&D Day

Eli Lilly and Company announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema.

Mesoblast Limited announced that U.S. FDA supports an accelerated approval pathway for rexlemestrocel-L, Mesoblast’s allogeneic mesenchymal precursor cell product, in patients with end-stage ischemic heart failure with reduced ejection fraction and a left ventricular assist device.

RemeGen Co. Ltd. recently gave an oral presentation on an interim analysis of the evaluation of the Company’s proprietary Disitamab Vedotin, an investigational anti-HER2 antibody-drug conjugate targeting prevalent solid tumor cancers with significant unmet medical needs, at the European Congress on Gynaecological Oncology held in Barcelona from March 7-10, 2024.